- Home
- HRMY vs VCEL Comparison
HRMY vs VCEL Comparison
Compare HRMY & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HRMY
- VCEL
- Stock Information
- Founded
- HRMY 2017
- VCEL 1989
- Country
- HRMY United States
- VCEL United States
- Employees
- HRMY N/A
- VCEL N/A
- Industry
- HRMY Biotechnology: Pharmaceutical Preparations
- VCEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HRMY Health Care
- VCEL Health Care
- Exchange
- HRMY Nasdaq
- VCEL Nasdaq
- Market Cap
- HRMY 2.1B
- VCEL 2.1B
- IPO Year
- HRMY 2020
- VCEL 1997
- Fundamental
- Price
- HRMY $32.29
- VCEL $33.23
- Analyst Decision
- HRMY Strong Buy
- VCEL Strong Buy
- Analyst Count
- HRMY 9
- VCEL 6
- Target Price
- HRMY $55.33
- VCEL $61.50
- AVG Volume (30 Days)
- HRMY 678.1K
- VCEL 729.6K
- Earning Date
- HRMY 10-28-2025
- VCEL 11-06-2025
- Dividend Yield
- HRMY N/A
- VCEL N/A
- EPS Growth
- HRMY 58.41
- VCEL 2045.40
- EPS
- HRMY 3.10
- VCEL 0.13
- Revenue
- HRMY $772,527,000.00
- VCEL $249,119,000.00
- Revenue This Year
- HRMY $20.09
- VCEL $18.35
- Revenue Next Year
- HRMY $16.86
- VCEL $22.47
- P/E Ratio
- HRMY $10.42
- VCEL $243.20
- Revenue Growth
- HRMY 17.74
- VCEL 16.13
- 52 Week Low
- HRMY $26.47
- VCEL $30.26
- 52 Week High
- HRMY $41.61
- VCEL $63.00
- Technical
- Relative Strength Index (RSI)
- HRMY 30.41
- VCEL 44.56
- Support Level
- HRMY $31.61
- VCEL $30.26
- Resistance Level
- HRMY $37.05
- VCEL $33.92
- Average True Range (ATR)
- HRMY 1.18
- VCEL 1.59
- MACD
- HRMY -0.59
- VCEL -0.10
- Stochastic Oscillator
- HRMY 10.19
- VCEL 44.93
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
About VCEL Vericel Corporation
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.